BRIEF-Terns Pharmaceuticals Says TERN-601 Well-Tolerated With Rapid Dose Titration

Reuters

Jun 24, 2025

June 23 (Reuters) - Terns Pharmaceuticals Inc TERN.O:

TERNS PHARMACEUTICALS PRESENTS POSITIVE DATA FROM PHASE 1 STUDY OF TERN-601 ONCE-DAILY ORAL GLP-1R AGONIST FOR TREATMENT OF OBESITY AT 85TH ANNUAL AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONS
TERNS PHARMACEUTICALS INC - TERN-601 WELL-TOLERATED WITH RAPID DOSE TITRATION
TERNS PHARMACEUTICALS- PHASE 2 FALCON CLINICAL TRIAL OF TERN-601 COMPLETED ENROLLMENT; 12-WEEK DATA EXPECTED IN 4Q 2025

Source text: ID:nGNX8X0HP

Further company coverage: TERN.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2545544053"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545544053\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2545544053?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-24 04:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545544053","market":"fut","top_or_hot":-1,"title":"BRIEF-Terns Pharmaceuticals Says TERN-601 Well-Tolerated With Rapid Dose Titration","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Terns Pharmaceuticals Says TERN-601 Well-Tolerated With Rapid Dose Titration</title></head><body><p><span>June 23 (Reuters)</span><span> - </span>Terns Pharmaceuticals Inc <span>TERN.O</span>:</p><ul><li><p>TERNS PHARMACEUTICALS PRESENTS POSITIVE DATA FROM PHASE 1 STUDY OF TERN-601 ONCE-DAILY ORAL GLP-1R AGONIST FOR TREATMENT OF OBESITY AT 85TH ANNUAL AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONS</p></li><li><p>TERNS PHARMACEUTICALS INC - TERN-601 WELL-TOLERATED WITH RAPID DOSE TITRATION</p></li><li><p>TERNS PHARMACEUTICALS- PHASE 2 FALCON CLINICAL TRIAL OF TERN-601 COMPLETED ENROLLMENT; 12-WEEK DATA EXPECTED IN 4Q 2025</p></li></ul><p>Source text: <span>ID:nGNX8X0HP</span></p><p>Further company coverage: <span>TERN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Terns Pharmaceuticals Says TERN-601 Well-Tolerated With Rapid Dose Titration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Terns Pharmaceuticals Says TERN-601 Well-Tolerated With Rapid Dose Titration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-24 04:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Terns Pharmaceuticals Says TERN-601 Well-Tolerated With Rapid Dose Titration</title></head><body><p><span>June 23 (Reuters)</span><span> - </span>Terns Pharmaceuticals Inc <span>TERN.O</span>:</p><ul><li><p>TERNS PHARMACEUTICALS PRESENTS POSITIVE DATA FROM PHASE 1 STUDY OF TERN-601 ONCE-DAILY ORAL GLP-1R AGONIST FOR TREATMENT OF OBESITY AT 85TH ANNUAL AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONS</p></li><li><p>TERNS PHARMACEUTICALS INC - TERN-601 WELL-TOLERATED WITH RAPID DOSE TITRATION</p></li><li><p>TERNS PHARMACEUTICALS- PHASE 2 FALCON CLINICAL TRIAL OF TERN-601 COMPLETED ENROLLMENT; 12-WEEK DATA EXPECTED IN 4Q 2025</p></li></ul><p>Source text: <span>ID:nGNX8X0HP</span></p><p>Further company coverage: <span>TERN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TERN","symbol_name":"Terns Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nFWN3SQ0UY:1","article_id":"2545544053","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545544053","pubTimestamp":1750711254,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Terns Pharmaceuticals Says TERN-601 Well-Tolerated With Rapid Dose TitrationJune 23 (Reuters) - Terns Pharmaceuticals Inc TERN.O:TERNS PHARMACEUTICALS PRESENTS POSITIVE DATA FROM PHASE 1 STUDY O","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TERN":"Terns Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"简介-Terns Pharmaceuticals表示TERN-601通过快速剂量滴定耐受性良好","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TERN":0.9},"content_text":"BRIEF-Terns Pharmaceuticals Says TERN-601 Well-Tolerated With Rapid Dose TitrationJune 23 (Reuters) - Terns Pharmaceuticals Inc TERN.O:TERNS PHARMACEUTICALS PRESENTS POSITIVE DATA FROM PHASE 1 STUDY OF TERN-601 ONCE-DAILY ORAL GLP-1R AGONIST FOR TREATMENT OF OBESITY AT 85TH ANNUAL AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONSTERNS PHARMACEUTICALS INC - TERN-601 WELL-TOLERATED WITH RAPID DOSE TITRATIONTERNS PHARMACEUTICALS- PHASE 2 FALCON CLINICAL TRIAL OF TERN-601 COMPLETED ENROLLMENT; 12-WEEK DATA EXPECTED IN 4Q 2025Source text: ID:nGNX8X0HPFurther company coverage: TERN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}